Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here, we leveraged the differential outcome in responders and non-responders to psilocybin (10 and 25 mg, 7 days apart) therapy for depression-to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used large-scale brain...
RSC Medicinal Chemistry2024Marthe Vandevelde, Andreas Simoens, Bavo Vandekerckhove et al.4 citations
Psilocybin analogues have been synthesized comprising a non-hydrolysable P–C bond to evaluate the biological activity and the selectivity towards 5-HT 2A R, 5-HT 2B R and the TNAP receptor.
Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of...
Background: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of the most widely studied classic psychedelics which has shown good safety and clinical benefit for major depression and substance use disorders. Athletes frequently sustain concussions and often experience myriad symptoms, including cognitive and mood...
Functional neurological disorder (FND) is a common cause of neurological symptoms including seizures and movement disorders. It can be debilitating, is associated with high health and social care costs, and can have a poor prognosis. Functional magnetic resonance imaging (fMRI) has suggested FND is a multi-network disorder. Converging evidence suggests that other mechanisms including...
Introduction and purpose: Nowadays, when mental disorders are considered by the World Health Organisation as a global burden, the potential usage of psychedelic drugs as supportive therapy is gaining more attention worldwide. The aim of this paper is to summarize the usefulness of psilocybin - representative of psychedelics - in psychiatric venues. In this review we describe its properties,...
The serotonergic psychedelic psilocybin acutely induces changes in emotional states. However, it remains unresolved whether psilocybin acutely modulates amygdala reactivity to emotions, a brain region critically involved in emotion processing. Using functional magnetic resonance imaging (fMRI), we examined in 26 healthy individuals whether amygdala responses to angry, fearful and neutral faces...
Mental illness is a hot topic of concern worldwide. The psilocybin has great potential in the treatment of mental disorders, but there is still a research gap on whether it can truly be applied in the treatment of mental disorders. Therefore, this research explores the feasibility of psilocybin’s true application in the treatment of mental disorders by collecting relevant literature on its...
Research SquareDecember 28, 2023Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al.1 citation
preprint
Abstract Background: Major Depressive Disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin...
Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin.Areas of Uncertainty: Despite initial concerns that psilocybin could cause...